AU - Abdel Monem, Marwa AU - El Sharkawy, Hamed AU - Abo ELezz, Ahmed AU - Ibrahim, Ashraf TI - Comparison of tadalafil and sildenafil in controlling neonatal persistent pulmonary hypertension PT - ORIG DP - 2014 Apr 1 TA - Egyptian Journal of Psychiatry PG - 89-94 VI - 35 IP - 2 4099- https://new.ejpsy.eg.net//article.asp?issn=1110-1105;year=2014;volume=35;issue=2;spage=89;epage=94;aulast=Abd;type=0 4100- https://new.ejpsy.eg.net//article.asp?issn=1110-1105;year=2014;volume=35;issue=2;spage=89;epage=94;aulast=Abd AB - Background Persistent pulmonary hypertension of the newborn (PPHN) is a multifactorial syndrome, with 0.43–6.8/1000 live birth incidence and 10–20% mortality rate. Aim To compare the efficacy of tadalafil and sildenafil in controlling PPHN. Patients and methods This prospective study was carried out on 40 neonates with PPHN. Patients were equally divided into two groups: group 1 received tadalafil (Cialis 10 mg), 1 mg/kg as a single dose for 48 h, and group 2 received sildenafil (Silden 25 mg), 1 mg/kg/8 h for 48 h. Echocardiography was done at the time of enrollment and 48 h after starting treatment measuring the change in estimated systolic pulmonary artery pressure (ESPAP), patent ductus arteriosus assessment, assessment of left ventricle functions, changes in oxygen saturation, and oxygen requirements. Results Both drugs were successful in improving oxygen saturation, decreasing oxygen requirements, and decreasing ESPAP. There was a significant difference before and after treatment in both groups, whereas the difference between the two groups was statistically insignificant (P>0.05). Conclusion Tadalafil and sildenafil can similarly reduce ESPAP in neonates with PPHN. No serious short-term adverse effects of tadalafil and sildenafil were observed.